Illustration

Beyond Anti-Angiogenesis

About Atengen

Atengen’s novel therapeutic target is expressed specifically in tumor blood vessels of most types of solid tumors but not in the blood vessels of healthy organs. Our scientists have used innovative technologies to identify several drug candidates that not only suppress tumor growth by inhibiting new blood vessel growth, but also cause extensive tumor necrosis by killing existing tumor blood vessels. In targeting the tumor blood supply rather than the tumor cells themselves, we can kill solid tumors in a tissue agnostic manner, while still maintaining a high degree of specificity. This groundbreaking approach has the potential to revolutionize the treatment of solid tumors.

A strategy to kill solid tumors in a tissue-agnostic manner

 Tumors depend on tumor blood vessels to grow and metastasize. We are developing a new generation of anti-angiogenic drugs designed to both inhibit and kill tumors by killing tumor blood vessels.

Atengen Blood Vessel Killing

Our Approach

We believe that our approach has several potential advantages compared to other solid tumor therapies that are currently available or in development.

Illustration

Specific Target

Our target is highly specific; it is only found in tumor blood vessels.

Illustration

Broad Target

At the same time, our target is very broad; it is present in the tumor blood vessels of most solid tumors.

Illustration

Kills Tumor Blood Vessels

Our approach disrupts new tumor blood vessel growth that is mediated by multiple different angiogenic factors and results in the death of existing tumor blood vessels.

Illustration

Suppress and Kill Solid Tumors

Our approach both suppresses tumor growth and kills existing tumors.

Illustration

Less Susceptible to Mutagenesis

Since we are not targeting cancer cells, our approach is less susceptible to mutagenesis.

Watch Our Video

Leadership

MANAGEMENT

SCIENTIFIC ADVISORY BOARD

  • Patrick Pool

    Pu Sun, PhD

    Co-Founder and Chief Executive Officer

    Dr. Sun is a co-founder of Atengen and has served as the company’s Chief Executive Officer since its founding in August of 2017. Prior to starting Atengen, Dr. Sun’s career focused on the development of automated and high throughput solutions for a broad spectrum of research areas, including small and large molecule pharmaceutical research. 

  • Andrew Wilson

    Joseph Sarret, MD, JD

    Chief Business Officer

    Dr. Sarret has served as Atengen’s Chief Business Officer since September 2019. He has over 15 years of experience in structuring and successfully implementing complex life sciences transactions. Prior to joining Atengen, he served as Chief Business Officer for Corium International, a commercial-stage biopharmaceutical company.

If you are interested in partnering with Atengen, please contact us.

Connect with Atengen

Send us an email: moc.negneta%40ofni or use the form below.

Thank you!

We will contact you shortly.

Can't send form.

Please try again later.